The word “adaptogen” is not a regulatory term. It is not a clinical category. It does not appear in any pharmacology textbook published before 1947, when a Soviet toxicologist named Nikolai Lazarev coined it to describe substances that “non-specifically increase the resistance of the organism to harmful influences.” For most of its history, the word lived inside a small community of Russian and Eastern European researchers studying stress physiology under conditions that Western pharmacology was — at the time — uninterested in.
And then around 2018, the word escaped. Today it is on the side of seltzer cans. The question for anyone trying to make an evidence-informed decision about whether to spend $40 a month on a powder is: does the clinical literature say what the marketing implies it says?
Ashwagandha: the most-studied of the bunch
Ashwagandha (Withania somnifera) has, by a comfortable margin, the strongest evidence base of any commercial adaptogen. A 2021 systematic review found 12 randomized controlled trials measuring its effect on perceived stress (mostly using the PSS-10 scale); the pooled effect size was meaningful, with most studies showing 25–35% reductions in self-reported stress over 8 weeks [1].
The standardized extract KSM-66 (5% withanolides) is the form used in the majority of trials, dosed at 600 mg/day. The cortisol-lowering effect — frequently cited in marketing — is real but modest: roughly a 20–30% reduction in morning serum cortisol over 60 days in stressed but otherwise healthy adults. Whether that translates to anything the user notices subjectively varies considerably.
“The trial-level signal for ashwagandha and perceived stress is real. The translation from a 25% PSS reduction into a felt experience is the harder claim.” — Dr. Adrian Lopresti, Murdoch University
Rhodiola: better for fatigue than for stress
Rhodiola rosea has a smaller but interesting evidence base, mostly clustered around mental and physical fatigue rather than emotional stress. A 2018 review of 11 trials found consistent moderate effects on fatigue scales, with the cleanest data coming from medical residents on overnight call and military personnel during sleep deprivation [2].
The active compounds — rosavin and salidroside — appear to modulate the HPA axis and adenosine signaling, though the exact mechanism is still debated. The recommended dose is 200–600 mg/day of an extract standardized to 3% rosavins.
Reishi: where the data thins out
Reishi (Ganoderma lucidum) is the adaptogen where the gap between marketing language and clinical evidence is widest. Most of the strong claims — anti-cancer, immune-modulating, longevity — rest on in-vitro and rodent data that has not been replicated in humans at any clinically relevant dose. The handful of human trials that exist are small, mostly underpowered, and produce mixed results.
That doesn’t mean reishi does nothing. It means the honest answer is: we don’t know yet.
The honest summary
If you want to try one adaptogen and want the most defensible evidence base behind your decision, the answer is ashwagandha — specifically the KSM-66 extract at 600 mg/day, taken for at least 8 weeks before assessing whether it’s doing anything for you. If you’re a shift worker or chronically sleep-deprived, rhodiola is worth considering. For reishi and most of the more exotic mushrooms, the data isn’t there yet — buy them because you enjoy them, not because the literature requires it.
[1] Lopresti AL et al. Medicine (Baltimore), 2021. [2] Ishaque S et al. BMC Complementary Medicine, 2012, updated 2018.